Clinical Trials
47 trialsNCT04513925 2026-06-03
SKYSCRAPER-03
Hoffmann-La Roche
Phase 3 Completed
NCT04619797 2026-06-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT04042558 2026-05-12
GFPC 06-2018
Centre Francois Baclesse
Phase 2 Completed
NCT02314481 2026-05-04
DARWINII
University College, London
Phase 2 Completed
NCT03563716 2026-05-04
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 2 Completed
NCT07192926 2026-02-20
SARCO-CTI
Ankara Etlik City Hospital
Completed
NCT06267001 2026-02-03
SKYSCRAPER-15
Hoffmann-La Roche
Phase 3 Completed
NCT04294810 2026-01-30
SKYSCRAPER-01
Hoffmann-La Roche
Phase 3 Completed
NCT04471428 2025-12-22
CONTACT-01
Hoffmann-La Roche
Phase 3 Completed
NCT05171777 2025-12-11
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03735121 2025-12-05
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02599454 2025-10-27
Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT03977467 2025-08-27
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT03285763 2025-01-23
TAIL
Hoffmann-La Roche
Phase 4 Completed
NCT03191786 2024-10-23
IPSOS
Hoffmann-La Roche
Phase 3 Completed
NCT03526900 2024-10-09
ATEZO-BRAIN
Spanish Lung Cancer Group
Phase 2 Completed
NCT02927301 2024-09-19
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
Genentech, Inc.
Phase 2 Completed
NCT03689855 2024-07-30
RamAtezo-1
Washington University School of Medicine
Phase 2 Completed
NCT04194203 2024-07-19
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
Hoffmann-La Roche
Phase 3 Completed
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT04426825 2024-05-21
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT03976518 2024-03-01
CHANCE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT02716038 2023-12-12
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Columbia University
Phase 2 Completed
NCT02657434 2023-11-21
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Hoffmann-La Roche
Phase 3 Completed
NCT02994576 2023-09-29
PRINCEPS
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03559647 2023-09-01
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
Hoffmann-La Roche
Completed
NCT03102242 2023-05-24
Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Alliance Foundation Trials, LLC.
Phase 2 Completed
NCT04059887 2023-02-08
BUDDY
Chonnam National University Hospital
Phase 4 Completed
NCT02813785 2023-01-10
IMpower210
Hoffmann-La Roche
Phase 3 Completed
NCT03922997 2022-09-09
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03232593 2022-08-24
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Hoffmann-La Roche
Completed
NCT03438318 2022-08-03
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 1 Completed
NCT03790397 2022-06-03
OSIREX
Fundación GECP
Completed
NCT03801304 2022-05-12
VinMetAtezo
University Hospital, Brest
Phase 2 Completed
NCT02366143 2021-09-23
IMpower150
Hoffmann-La Roche
Phase 3 Completed
NCT02848651 2020-04-28
B-F1RST
Genentech, Inc.
Phase 2 Completed
NCT02013219 2020-04-21
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 1 Completed
NCT02031458 2020-01-06
BIRCH
Hoffmann-La Roche
Phase 2 Completed
NCT03023423 2019-11-20
DARZALEX
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT01903993 2019-10-02
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
Hoffmann-La Roche
Phase 2 Completed
NCT02463994 2019-02-08
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT01846416 2019-01-08
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Genentech, Inc.
Phase 2 Completed